Seres Therapeutics Earnings Reports

Seres Therapeutics' Q4 2024 revenue was classified under discontinued operations due to the sale of its VOWST business. The company reported a net loss of $15.7 million, a significant improvement from the $34.7 million loss in Q4 2023. Operating expenses decreased as the company streamlined its focus on SER-155. Cash and cash equivalents stood at $30.8 million, with additional funding expected from Nestlé in mid-2025.

Seres Therapeutics reported a net loss from continuing operations of $51 million for the third quarter of 2024. The company's financial position was strengthened by the VOWST sale, and they anticipate funding operations into Q4 2025.

Seres Therapeutics reported a net loss of $32.9 million for the second quarter of 2024. The company's VOWST asset sale is expected to provide a $175 million cash infusion, which will be used to retire debt and advance the company's pipeline.

Seres Therapeutics reported VOWST net sales of $10.1 million in Q1 2024, with approximately 1,411 patient enrollment forms received and approximately 1,083 new patient starts. The company's net loss for the quarter was $40.1 million, as compared to a net loss of $71.2 million for the same period in 2023.

Seres Therapeutics reported VOWST net sales of $10.4 million for the fourth quarter of 2023. The company's net loss for the quarter was $41.2 million, as compared to a net loss of $68.8 million for the same period in 2022.